Background: The influenza A(H1N1)2009 virus has been the dominant type of influenza A virus in Finland during the
Introduction
During the recent two years, the pandemic influenza A virus of swine origin, influenza A(H1N1)2009 virus, has been the predominant circulating influenza virus in most parts of the world. The virus has infected millions of people and the infection has lead to the death of at least 18 400 individuals. In Finland the first cases of the influenza A(H1N1)2009 were identified in May 2009. During September the first local outbreaks occurred in garrisons and schools, after which the virus spread rapidly in the general population. The peak pandemic activity was observed during weeks 43-49 and by the end of the year the epidemic was over in Finland [1, 2] . During the 2010-2011 epidemic season influenza A(H1N1)2009 viruses were identified from the beginning of December 2010 until middle of March 2011.
In serosurveys elderly individuals were found to have preexisting, cross-reactive antibodies against the novel 2009 pandemic virus that were likely originating from previous infections with antigenically related viruses such as the 1918 influenza virus and its immediate descendants that were circulating during the early decades of the 20 th century [3] [4] [5] [6] [7] [8] . Except for the elderly, large segments of the human population throughout the world lacked protective immunity against the novel influenza A(H1N1)2009 virus and were thus susceptible to the virus infection. Until now, likely due to limited immunological pressure in the general population, the virus has not yet undergone significant genetic or antigenic changes.
Through the hemagglutinin (HA) the influenza virus binds to sialic-acid receptors on the host cell surface, after which the virus is internalized and the viral genome enters the nucleus in order to initiate viral RNA synthesis. Since the HA is situated on the surface of the viral particles it is also a target for immune response, especially antibodies. The major antigenic epitopes in the HA molecule mutate frequently enabling the virus to escape immune responses. Recent reports on the evolution of influenza A(H1N1)2009 describe mutations S183P (amino acid numbering throughout the text starts from the mature HA0 without signal peptide) and I191L in HA that enhance viral replication in cell culture and in embryonated hens' eggs [9] . Other mutations, such as D127E, S183P and D222G have been shown to be associated with a more virulent phenotype in humans or mice [2, [10] [11] [12] . The D127E and S183P mutations have lead to antigenic changes and impaired recognition by ferret antisera raised against the A/California/07/2009 virus [11] . Recently, a new frequently observed mutation, E374K has been found [13] . This mutation locates in the HA oligomerization interface and is also part of a known antigenic site. This mutation is not unambiguously associated with severe disease, but interestingly it has been detected in pandemic vaccine breakthrough infections. These viruses typically had N125D substitution in their HA molecule [14] . During the year 2010 viruses with double mutations N125D and E374K have been found with increased frequency in the southern hemisphere [14] . These viruses have been associated with several vaccine breakthrough infections and were identified in a number of fatal cases [14] . The N125D mutation is located in the Sa epitope of A(H1N1)2009 HA [2] and in an avian influenza strain (A/ Mallard/Pennsylvania/10218/84(H5N2)) the corresponding amino acid was reported to cause antigenic drift as an immune escape mutant [15] . However, antigenic analysis with ferret anti-sera showed no remarkable differences in antibody titers against the N125D virus as compared to the A/California/07/2009 vaccine virus [14] .
Genetic characterization of the influenza A(H1N1)2009 viruses that circulated in Finland and elsewhere during 2009 show that these viruses were closely related to A/California/07/2009 vaccine virus [2, 6, 16] . At present, genetic analyses of the HA or neuraminidase (NA) genes do not reveal any changes that may have led to the selection of a virus with increased epidemic potential or exceptionally high virulence. However, the antigenic characteristics of these viruses have not been systematically analyzed in humans. Here we report that several amino acid changes, namely N125D, N156K, S162R, and E374K, are associated with reduced recognition by sera collected from patients having experienced natural A(H1N1)2009 infection or having received vaccination as analyzed by the hemagglutination inhibition (HI) test. Especially, double mutations N125D and N156K (2009 virus isolate) or N125D and E374K (2010 virus isolates) were associated with declined antibody recognition in vaccinated individuals. (Figure 2 ). This mutation has also been detected globally in majority of influenza A(H1N1)2009 viruses [18] . In addition to this common change, most of the Finnish A(H1N1)2009 viruses showed one or two additional amino acid changes in other antigenic epitopes. Of potential interest in respect to antibody recognition is the group I/2009-2010 virus, A/Finland/694/2009, which has N125D and N156K amino acid substitutions on the distal end of the HA molecule locating to the antigenic site Sa (Figure 2 and Figure S2 ). In addition, novel double mutations (N125D and E374K) were also found in the group II/2010-2011 viruses, namely in A/Finland/19/2010 and A/Finland/22/2010 viruses. The amino acid change E374K has been identified in some A(H1N1)2009 viruses isolated in Finland ( Figure 1 ) and elsewhere [2, 13, 14] . Additional mutations at potential antigenic sites, in relation to the California vaccine virus, were also identified at positions 73, 74, 137, 162, 185, and 222 ( Figure 2 and Figure S2 ). (Figure 2 and Figure S2 ).
Results

Analysis
Antibody titers for cell culture-grown viruses correlate with egg-propagated virus in HI test Figure 3A and B) . Correlation coefficients for all tested viruses were significant, p,0.001, which suggested that MDCK-and egg-grown viruses were comparable in HI test. However, the scatter blots in Figure 3 
The elderly have broad-spectrum low-level cross-reactive antibodies against pandemic influenza viruses
We have previously reported that older Finns had cross-reactive antibodies against the pandemic influenza A(H1N1)2009 virus providing potential protection against the infection [4] . We tested a set of serum samples collected in 2005 from individuals whose age was at that time 80 years or over. Among these elderly individuals the antibody titers against the current pandemic viruses were generally low (range of . In addition, contrary to patient sera where the antibodies failed to recognize some of the tested viruses, in the elderly none of the tested viruses, except the vaccine strains, were distinguishable in HI test ( Figure 4B ). This may indicate that infections of the elderly by the Spanish influenza and/or its immediate descendant viruses were able to induce quite broad-spectrum cross-reactive humoral immunity against the pandemic influenza A(H1N1)2009 virus. The significance of the differences was not calculated since none of the studied viruses can be set as a baseline. On the other hand, as compared to the A/ California/07/2009 vaccine virus the antibody titers against all the Finnish strains were higher. these viruses and whether the viruses with mutations in antigenic sites can escape from vaccine-induced immunity. Analysis of serum specimens from twenty vaccinated healthy adults showed that 21 days after vaccination anti-influenza antibodies showed a five to fifteen-fold increase in geometric mean titers against all viruses, except that of A/Finland/694/2009 with only less than a three-fold increase ( Figure 5A ). One year after the vaccination, the mean antibody levels against most studied viruses had clearly decreased but they were still three-to six-folds higher as compared to prevaccination antibody levels. Serum specimens from guinea pigs were collected only at day 0 before the first immunization and one week after the last vaccination. Mean antibody levels increased to very high levels after four doses of vaccine and antibody titers against most viruses were at a comparable level. The only exception was again the A/Finland/694/2009 virus, against which the antibodies remained at much lower level as compared to other viruses ( Figure 6B ). This suggests that even multiple doses of the vaccine failed to induce highly cross-reactive antibodies against this virus which carries two mutations in antigenic site Sa (Figure 2 and Figure S2 ). vaccine in rabbits and guinea pigs. Rabbits (A) and guinea pigs (B) were immunized four times at three weeks intervals with pandemic influenza A(H1N1) vaccine and the serum samples were collected on day 0 (rabbits and guinea pigs), before each immunization (rabbits), and one week after the last immunization (rabbits and guinea pigs). The immunizations (black) and sample collections (grey) are marked with arrows. The serum samples were analyzed by HI test and geometric mean titers for each virus were calculated. The means represent the geometric means of three rabbit and five guinea pig anti-sera. doi:10.1371/journal.pone.0025848.g006
vaccine candidate for the 2011-2012 vaccine to be used in the northern hemisphere. This virus is still assumed to give reasonable protection against infection with globally circulating viruses. However, even few amino acid changes in antigenically important sites of the HA, as demonstrated in the present study, may render the vaccine virus a poor match to the circulating virus strains.
The HA protein on the surface of influenza virions is one of the major target molecules for host antibody responses. Therefore, amino acid changes occurring either in the antigenic sites or on the surface of the HA molecule may have an important effect on antibody recognition. Five classical antigenic sites (Sa, Sb, Ca1, Ca2, and Cb) have been described in the HA of influenza A/ H1N1 virus [20, 21] . These antigenic sites are located at the globular head of the HA (Figures 1, 2 , and S2) although recent studies have described antigenically important determinants also in the stem region of HA [22] [23] [24] An important question is whether antibody levels and the broadness of cross-reactivity against different virus strains can be stimulated by repeated immunizations with pandemic influenza A(H1N1)2009 vaccine. Since the Finnish population received only one dose of the pandemic vaccine before or during the pandemic we used experimental animals to study the effect of repeated immunizations on antibody responses and cross-reactivity. In rabbits, it was found that already two doses of the pandemic influenza A(H1N1)2009 vaccine were sufficient to induce maximal or near-maximal antibody responses against different epidemic virus strains. Interestingly, repeated immunizations were not able to expand the cross-reactivity against different viruses since the antibody ratios against different virus isolates vs. the vaccine virus strain remained rather constant ( Figure 6A ). This may indicate that the initial specificity of the antibody response is determined at early times of immunization and repeated immunizations with the same vaccine, such as the Pandemrix vaccine, does not lead to broadening of the specificity of the antibody response. These findings may indicate that also in humans, in order to induce better antibody cross-reactivity, the composition of the vaccine has to be changed rather than giving repeated immunizations with the same vaccine.
The present study demonstrates that circulating influenza A(H1N1)2009 viruses are genetically highly diverse and at present a specific globally circulating virus strain has not been observed. Genetic characterization of the Finnish circulating viruses, which originated from different parts of the world, indicates that the evolutionary speed of the virus is quite typical for influenza A viruses. However, there appears to be a tendency that many viruses have mutations in antigenically important epitopes of the HA molecule and these mutations may have quite dramatic effects on antibody recognition both among vaccinated individuals and those that had experienced a natural infection. Thus, continuous genetic and antigenic surveillance of circulating influenza viruses as well as rapid and open sharing of information is of utmost importance for WHO to make the best possible recommendation for the vaccine viruses. In addition, it is important to rapidly identify virus strains with elevated virulence or with the ability to escape vaccine-or natural infection-induced immunity. 
Materials and Methods
Viruses
Sequence and phylogenetic analysis of HA gene
The nucleotide sequences of the influenza A(H1N1)2009 viruses for this study (35 Finnish strains from the epidemic season 2010-2011) were sequenced from original clinical samples. RNA extraction, cDNA synthesis, DNA amplification and sequencing were performed as previously described [2] . The nucleotide sequences of the complete HA genes were assembled using Sequencer version 4.7 (Gene Codes Corporation, Ann Arbor, USA). Mega software version 4 [26] (Molecular Evolutionary Genetics Analysis) was used in nucleotide and amino acid sequence comparison and for the construction of the phylogenetic tree. The Neighbor-joining method [27] with the maximum composite likelihood model [28] was used to generate the phylogenetic tree. Bootstrapping was performed with 1000 replicates [29] . In the present study all HA amino acid residues are numbered without the signal peptide sequence.
GenBank 
Immunizations of rabbits and guinea pigs
In order to study the immunogenicity and the ability of the pandemic influenza A(H1N1)2009 vaccine to induce cross-reactive antibody responses in animals we immunized five guinea pigs and three rabbits four times in three weeks intervals. Each animal received one human dose (3,75 mg HA in AS03 adjuvant) of vaccine with each immunization. Serum samples from guinea pigs were collected before the first immunization (day 0) and one week after the last immunization (day 70). From the rabbits serum samples were collected on day 0, before each immunization on days 21, 42, and 63, and one week after the last immunization on day 70. Immunizations of the animals and the collection of serum samples were approved by the Ethical Committee of National Institute for Health and Welfare (permission KTL 2008-02). Serum samples were stored at 220uC and analyzed for influenza A virus specific antibodies by the HI test. [31, 32] using turkey erythrocytes. In brief, serum samples were pretreated with receptor destroying enzyme (RDE) from Vibrio cholerae filtrate (Denka Seiken, Tokyo, Japan) at +37uC for 18 h and then with 100% turkey erythrocytes at +4uC for one hour to remove nonspecific inhibitors and agglutinins. Serial 1:2 serum dilutions starting from 1:10 initial dilution were made, live viral antigen (4 HA units) was added and incubated for one hour at ambient temperature. Turkey red blood cells (0.5%) were added to antigenserum solutions and incubated at room temperature for 30 minutes to determine the HI titers. Serum specimens with HI titers ,10 were assigned a titer value of 5 for statistical analyses.
Serologic assays
Statistical analysis
Antibody titers obtained by the HI test were analyzed statistically by calculating geometric mean titers with 95% confidence intervals for each virus. Significance of the differences between mean titers for each virus compared to the vaccine strain was calculated using Student's t-test (paired, two-tailed) and the significance level was adjusted to p,0.01. The correlation coefficient and the significance of the correlation coefficient of the antibody titers for each virus were calculated against the A/ California/07/2009 egg-grown virus. 
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